Aurora cannabis announces fiscal 2025 second quarter results

Nasdaq | tsx: acb record adjusted ebitda1 of $10.1 million, a yoy increase of 210% quarterly net revenue1 up 29% yoy to $81.1 million, with 41% growth in global medical cannabis re-affirms target of positive free cash flow1 in the quarter ending december 31, 2024 maintains strong balance sheet with ~$152 million of cash and a debt-free cannabis business2 edmonton, ab , nov. 6, 2024 /prnewswire/ - aurora cannabis inc. (the "company" or "aurora") (nasdaq: acb) (tsx: acb), a leading canada-based global medical cannabis company, today announced its financial and operational results for the second quarter fiscal 2025. "our strong quarterly results demonstrate aurora's leadership in global medical cannabis and ability to capitalize on opportunities within rapidly growing markets such as australia, germany, poland, and the uk.
ACB Ratings Summary
ACB Quant Ranking